Regulatory & commercial reality
Therapeutic EV products should be assumed to require IND-enabled development and GMP manufacturing. Cash-pay exosome clinics are not a credible venture pathway.
FDA posture (no approved exosome products)
Exosomes intended to treat disease are regulated as drugs and biological products requiring premarket approval. There are currently no FDA-approved exosome products.
Use-case practicality matrix
| Use case | Practicality | Rationale | Sources |
|---|---|---|---|
| Topical/local wound healing EVs | Moderate | Local delivery, visible endpoints, lower systemic exposure; still needs potency and sterility. | |
| Ophthalmology/local tissue repair | Moderate | Small volumes and local delivery help; formulation burden remains high. | |
| Inhaled EVs for lung injury | Moderate-low | Strong biology, but aerosol stability, dose, biodistribution, and inflammation risk matter. | |
| Systemic anti-inflammatory MSC-EVs | Low-moderate | Large doses, unclear biodistribution, variable potency. | |
| Oncology immune-modulating EVs | Low-moderate | High bar, complex tumor biology, hard clinical differentiation. | |
| Engineered EV delivery of RNA/protein | Moderate (capital-intensive) | More drug-like, but must beat LNPs, AAV, conjugates, and other delivery technologies. | |
| Cosmetic/aesthetic exosomes | Commercially active / regulatory-risky | Demand exists, but claims, sourcing, and quality vary; not a therapeutic IND pathway. |
ISEV regulatory resources
ISEV guidance complements FDA: how EV trials, potency, and agency engagement are usually framed. Not a substitute for IND advice or company-specific regulatory counsel.